Software & SaaS

As restaurants face economic headwinds, a new AI platform is empowering servers, enhancing guest experience, and promising to double bottom-line profits.

For patients with slow-growing lymphoma, "watch-and-wait" can be agonizing. A novel immunotherapy is showing promise in replacing anxiety with action.

CityHealth's 2025 report shows local policy is potent medicine. Discover how cities like Chicago are using data to tackle health, from housing to greenspace.

A landmark report reveals corporate commitment to women's advancement is plummeting, creating an ambition gap that threatens to erase a decade of progress.

A top global forum warns of politicized trade and tech divides. How will this impact pharma supply chains, AI in medicine, and market access?

Netcapital's huge 1M share grant to its new CEO is a high-stakes play. We decode the strategy, the risk, and the ambitious revenue targets.

As Thailand braces for another toxic smog season, air purifier giant Levoit deploys a timely strategy to capture a market born from a public health crisis.

A Japanese chemical plant's new AI-powered microgrid reveals how firms are using renewables not just for ESG, but as a defense against disaster and grid failure.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

Broadway star Morgan Dudley returns to the tech platform that discovered her. Can her insider role help Stargaze win the high-stakes talent-tech race?

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Facing an OSC probe and audit delays, the legal tech firm is now seeking court relief, raising red flags for investors about its governance and finances.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

SRN Advisors is consolidating its dividend ETFs, shifting from a defensive strategy to pure growth and highlighting a major consolidation trend in finance.

Vapotherm partners with Flight Medical, launching the VentO2ux ventilator to challenge market giants and redefine emergency respiratory care in the US.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

The biggest obstacle to the EV revolution might be under your feet. One company's simple, award-winning solution to a muddy problem is changing the game.

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

Lifestyle experts are shaping your holiday shopping. We dissect the strategy behind curated gift guides, influencer endorsements, and the media firms driving them.